Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2023-01-04 00:00:00 ET · period of report 2022-12-30 · accession 0000899243-23-000648 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-04 | 2022-12-30 | LGND | Espinoza Octavio | CFO | J - Other | $56.78 | +275 | 18.9K | +1% | +$15.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-30 | J | A | 275 | $56.78 | 18,945 | D | — | — |